Rheumatoid Arthritis Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

November 08 21:37 2022
Rheumatoid Arthritis Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Rheumatoid Arthritis Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Rheumatoid Arthritis (RA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Rheumatoid Arthritis Pipeline Report

  • DelveInsight’s Rheumatoid Arthritis Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Rheumatoid Arthritis.
  • The leading Rheumatoid Arthritis Companies such as Abivax, Kymera Therapeutics, Akari Therapeutics, Sierra Oncology, Neutrolis Therapeutics, Centivax, Taisho, Hope Biosciences, UCB, Galmed Pharmaceuticals, Celon Pharma, Jiangsu Hengrui Medicine Co., Cyxone, Oryn Therapeutics, and others.
  • Promising Rheumatoid Arthritis Pipeline therapies such as M2951, etanercept, M2591 25 mg QD, Mavrilimumab 30 mg, Adalimumab, methotrexate, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis.
  • In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Get an overview of the Rheumatoid Arthritis Pipeline landscape @ Rheumatoid Arthritis Emerging Therapies

 

Rheumatoid Arthritis Overview

Rheumatoid Arthritis is called an autoimmune condition. It starts when your immune system, which is supposed to protect you, goes awry and begins to attack your body’s own tissues. It causes inflammation in the lining of your joints (the synovium). As a result, joints may get red, warm, swollen, and painful. RA affects joints on both sides of the body, such as both hands, both wrists, and both knees. This symmetry helps to set it apart from other types of arthritis. Over time, RA can affect other body parts and systems, from eyes to heart, lungs, skin, blood vessels, and more. The warning signs of RA are: Joint pain and swelling Stiffness, especially in the morning, Fatigue. Rheumatoid arthritis affects everyone differently. For some, joint symptoms happen gradually over several years. In others, it may come on quickly. Some people may have rheumatoid arthritis for a short time and then go into remission, which means they don’t have symptoms. The disease is two to three times more common in women than in men, but men tend to have more severe symptoms.

 

Latest Breakthroughs of the Rheumatoid Arthritis Treatment Landscape

  • BAY 1830839 is a novel small molecule inhibitor of IRAK4 identified by a medicinal chemistry optimization program. Key features of the compound are high potency (IC50 of 3 nM) in a biochemical assay, excellent kinase selectivity and a good overall PK profile making the compound a valuable tool for in vivo studies. The drug is being investigated in Phase 1 stage of development for the treatment of Rheumatoid Arthritis.
  • Ianalumab is an anti-B-cell activating factor (BAFF) receptor antibody which is administered subcutaneously. The drug is being investigated in Phase 2 stage of development for the treatment of Rheumatoid Arthritis.
  • ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA, called miR-124, with potent anti-inflammatory properties. ABX464 showed a very favorable tolerability profile with mainly mild to moderate and transient side effects.
  • Ozoralizumab (ATN-103) is a trivalent humanized low molecular weight compound that combines two anti-TNFα NANOBODY® VHHs and one anti-serum albumin NANOBODY® VHH. Ozoralizumab is about a quarter of the size of conventional IgG antibodies. Ozoralizumab binds to two subunits of TNFα and potently neutralizes its action. Ozoralizumab, initially discovered by Ablynx. In March 2021, Taisho announced that it submitted an application for approval to manufacture and market the anti-TNFα NANOBODY® therapeutic (generic name: ozoralizumab) to the Ministry of Health, Labour and Welfare for rheumatoid arthritis (RA).

 

Request a sample and discover the recent advances in Rheumatoid Arthritis treatment drugs @ Rheumatoid Arthritis Pipeline Report

 

Rheumatoid Arthritis Emerging Drugs

  • Ozoralizumab: Taisho Pharmaceutical
  • ABX 464 : Abivax
  • Ianalumab:Novartis
  • BAY1830839:Bayer

 

DelveInsight’s Rheumatoid Arthritis Pipeline Report covers around 120+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the emerging Rheumatoid Arthritis pipeline therapies @ Rheumatoid Arthritis Clinical Trials

 

Scope of the Rheumatoid Arthritis Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment
    • Assessment by Product Type
    • Assessment by Stage and Product Type
    • Assessment by Route of Administration
    • Assessment by Stage and Route of Administration
    • Assessment by Molecule Type
    • Assessment by Stage and Molecule Type
  • Rheumatoid Arthritis Companies- Abivax, Kymera Therapeutics, Akari Therapeutics, Sierra Oncology, Neutrolis Therapeutics, Centivax, Taisho, Hope Biosciences, UCB, Galmed Pharmaceuticals, Celon Pharma, Jiangsu Hengrui Medicine Co., Cyxone, Oryn Therapeutics, and others.
  • Rheumatoid Arthritis Therapies- M2951, etanercept, M2591 25 mg QD, Mavrilimumab 30 mg, Adalimumab, methotrexate, and others.

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Rheumatoid Arthritis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Rheumatoid Arthritis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Ozoralizumab : Taisho Pharmaceutical
  9. Mid Stage Products (Phase II)

10. ABX464 : Abivax

11. Early Stage Products (Phase I)

12. BAY1830839: Bayer

13. Preclinical and Discovery Stage Products

14. Inactive Products

15. Rheumatoid Arthritis Key Companies

16. Rheumatoid Arthritis Key Products

17. Rheumatoid Arthritis- Unmet Needs

18. Rheumatoid Arthritis- Market Drivers and Barriers

19. Rheumatoid Arthritis- Future Perspectives and Conclusion

20. Rheumatoid Arthritis Analyst Views

21. Rheumatoid Arthritis Key Companies

22. Appendix

 

For further information on the Rheumatoid Arthritis pipeline therapeutics, reach out @ Rheumatoid Arthritis Treatment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/